

Instructions for Authors

Scope

Cancer Epidemiology, Biomarkers & Prevention publishes original research on cancer causation and prevention in humans. The following topics are of special interest: descriptive, analytical, biochemical and molecular epidemiology; the use of biomarkers to study the neoplastic and preneoplastic processes in humans; chemoprevention and other types of prevention trials; and the role of behavioral factors in cancer etiology and prevention.

Particular attention will be given to the identification of factors associated with various aspects of the carcinogenic process, including genetic susceptibility, host factors, infectious agents, chemical and physical carcinogens, environmental contaminants, dietary components and behavioral factors such as tobacco use and sun exposure.

Besides welcoming manuscripts that address individual subjects in any of the three disciplines, the Editors encourage the submission of manuscripts with an interdisciplinary approach.

Contents

- Original research articles
- Invited editorials
- Selected review articles
- Short communications
- Letters to the editor
- Meeting reports
- AACR and ASPO news

Editorial Policy

When a manuscript is received for consideration, the Editors assume that no similar paper has been or will be submitted for publication elsewhere. Further, it is understood that all authors listed on a manuscript have agreed to its submission. Upon acceptance, authors must transfer copyright to the American Association for Cancer Research, Inc., the publisher and copyright owner of the journal, prior to publication. The Editors endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving humans will have been performed in accordance with these principles. A copy of the Declaration is available from the World Medical Association, 28, Ave. des Alpes, F-01210, Ferney-Voltaire, France.

Journal policy requires that authors, reviewers, and Associate Editors reveal to the Editor-in-Chief any relationships that they believe could be construed as causing a conflict of interest with regard to the manuscript submitted for review.

Manuscript Submission

Mail manuscripts directly to Dr. Pelayo Correa, Editor-in-Chief. Submit four original sets (not photocopies) of illustrations along with four copies of the manuscript. Illustrations will be returned to the author if the paper is not accepted for publication. If a manuscript is closely related to papers that are in press or have been submitted elsewhere, please provide copies of those papers with your submission. FAX transmission and overnight delivery service will be used to expedite review and publication.

Publication Fees

A page charge of \$35 per printed page will be levied on all manuscripts accepted for publication. It is understood at the time of submission that the author(s) agree to pay this charge in the event of publication. Under exceptional circumstances, when no other source of grant or other support exists, the author(s) may apply to Dr. Margaret Foti, Director of Publications, AACR Publications Department (see end of page for address) at the time of submission for a waiver of the page charges. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges.

Format

Manuscripts must be written succinctly in clear, grammatical English. Define abbreviations in an inclusive footnote to the text. Double-space on 8 1/2 × 11-inch paper. Dot-matrix printing is not acceptable. The format is as follows:

1. Title page, including title, authors, and affiliations;
2. A running title of fewer than 50 characters;
3. Text, arranged in this order: Abstract (not more than 250 words), Introduction, Materials and Methods, Results, Discussion, Acknowledgments, References;

4. Footnotes, on a page separate from the text. Designate footnotes consecutively with superscript Arabic numerals;
5. Tables, on pages separate from the text, with descriptive titles and/or legends;
6. Figure legends, on pages separate from the text. Define all symbols and include staining for halftones, where applicable.

References

Include only those articles that have been published or are in press. Unpublished data or personal communications must be cited as footnotes to the text. Personal communications should be substantiated by a letter of permission.

Number references in the order of their first mention in the text. Cite only the number assigned to the reference. References must be double-spaced.

Sample references:

1. Fontham, E. T. H., Correa, P., Wu-Williams, A., Reynolds, P., Greenberg, R. S., Buffler, P. A., Chen, V. W., Boyd, P., Alterman, T., Austin, D. F., Liff, J., and Greenberg, S. D. Lung cancer in nonsmoking women: A multicenter case-control study. *Cancer Epidemiol., Biomarkers & Prev.*, 1: 35-43, 1991.
2. Reznikoff, C. A., Swaminathan, S., and Verma, A. K. Cultured normal human uroepithelial cells: a new system for *in vitro* carcinogenesis studies. In: M. Webber and L. Sikeley (eds.), *In Vitro Models for Cancer Research*, pp. 63-101. Boca Raton, FL: CRC Press, 1986.

Illustrations

Provide four original sets of illustrations (whether line-cut drawings or halftones). Label each figure in pencil on the reverse side with the first author's name, figure number, and an arrow indicating top of figure. Letters and numbers on illustrations should not be smaller than 6-point or larger than 12-point type. All illustrations will be published at a width of approximately 3 inches (8 cm) unless the author requests a greater width. Use tissue overlays to indicate important areas of the photographs that must be reproduced with the greatest fidelity.

Authors are encouraged to submit color figures. The expense of reproducing color photographs must be offset partially by the author. In 1996, the cost of color reproduction charged to authors will be **\$975 per color figure**. Submit color illustrations on flexible backing.

Proofs

Page proofs must be returned to the office of the American Association for Cancer Research within 24 hours of receipt. Return proofs by overnight mail. **Proofs not received by the deadline will be published without the authors' corrections.** Accepted manuscripts are regarded as final copy and should not be altered substantially in proof. Extensive alterations could cause publication delays, and authors will be charged for excessive changes in proof.

Typesetting Manuscripts from Computer Disks

Cancer Epidemiology, Biomarkers & Prevention welcomes disks to expedite production of accepted manuscripts. If your article is accepted for publication, you will receive instructions regarding disk submission and a form which must be completed and returned with your disk to the AACR Publications Department within 48 hours of notification of acceptance. It is the author's responsibility to ensure that the material on the disk matches the final accepted version of the manuscript.

For More Information, Contact:

Dr. Pelayo Correa, Editor-in-Chief, CEBP, Department of Pathology, Louisiana State University Medical Center, 1901 Perdido Street, New Orleans, LA 70112-1393. Telephones: (504)529-2848; (504)568-6035; FAX: (504)529-2849.

Or:

Publications Department, American Association for Cancer Research, Public Ledger Building, 150 South Independence Mall West, Suite 816, Philadelphia, PA 19106-3483. Telephone: (215)440-9300; FAX: (215)440-9355.

AMERICAN ASSOCIATION FOR CANCER RESEARCH

BENEFITS OF MEMBERSHIP



The American Association for Cancer Research (AACR) is a scientific society consisting of laboratory and clinical cancer researchers. It was founded in 1907 and its purposes are "to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world." Members of the AACR enjoy the following benefits:

1. the opportunity to subscribe to the journals *Cancer Research*, *Cell Growth & Differentiation*, *Cancer Epidemiology, Biomarkers & Prevention*, and *Clinical Cancer Research* at the reduced member rate.
 - *Cancer Research* publishes over 7,000 pages per year of timely, significant research. With over 40,000 citations to its articles per year, it rates as the most highly cited journal in the cancer field.
 - *Cell Growth & Differentiation*, a journal of the molecular biology of cancer, has established a tradition of rapid publication with an average review time of 2-3 weeks and an average of 10 weeks between acceptance and publication.
 - *Cancer Epidemiology, Biomarkers & Prevention* has already established itself as a leading journal with a wholly unique scope, providing a common forum for three scientific areas that are rapidly expanding our knowledge of cancer causation and prevention in humans.
 - *Clinical Cancer Research*, the AACR's newest journal, began publication in 1995. Focusing on innovative translational studies, it publishes original laboratory and clinical research on the molecular characterization, prevention, diagnosis, and therapy of human cancer.
2. the privilege of sponsoring a paper for possible presentation at the AACR Annual Meeting;
3. an advance copy of the Program and, if one has been purchased, *Proceedings* pertaining to each Annual Meeting;
4. reduced registration rates at Annual Meetings;
5. priority notice of and reduced registration rates for small, focused meetings in the AACR's Special Conferences in Cancer Research;
6. opportunities for participation in the AACR's meetings with other scientific societies around the world;
7. subscriptions to future AACR journals at reduced member rates;
8. the receipt of AACR newsletters and meeting announcements;
9. early notification of and reduced rates for participation in the Employment Register;
10. an up-to-date Membership Directory;
11. participation in Summer Workshops that foster networking opportunities and science education for young investigators;
12. the benefits of the AACR's public education activities concerning funding for cancer research and press coverage of the latest research findings; and
13. many more ongoing benefits.



AMERICAN ASSOCIATION FOR CANCER RESEARCH

GUIDELINES FOR APPLICATION FOR ACTIVE AND CORRESPONDING MEMBERSHIP

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society of over 10,000 laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage the presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting;
2. an advance copy of the Program and *Proceedings of the American Association for Cancer Research* pertaining to each annual meeting;
3. reduced registration rates at annual meetings;
4. priority notice of small, focussed meetings in the AACR's exciting series of Special Conferences in Cancer Research;
5. reduced registration rates for Special Conferences;
6. opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
7. receipt of AACR Newsletters and other important announcements;
8. early notification of and reduced rates for participation in the AACR Employment Register;
9. an up-to-date Membership Directory of thousands of researchers in the cancer field;
10. the professional benefits of the AACR's public education activities concerning funding for cancer research and press coverage of the latest research findings;
11. participation in Summer Workshops that foster networking opportunities and science education for young investigators; and
12. many more ongoing benefits.

QUALIFICATIONS FOR MEMBERSHIP

Active membership in the AACR is open to investigators who live in the Americas. Individuals who have conducted two years of research resulting in peer-reviewed publications relevant to cancer, or who have made substantial contributions to cancer research in an administrative or educational capacity, are eligible. If a candidate has conducted research in an area of biomedical science related to cancer, he or she will qualify for membership. Evidence of patents relevant to cancer research may be submitted as qualifications for membership in lieu of peer-reviewed publications.

Corresponding membership is open to persons who are not residents of the Americas. The qualifications for corresponding membership are the same as those indicated above for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin by the anticipated time of election should apply for corresponding membership. All other visiting scientists should apply for active membership and transfer to corresponding status upon leaving the Americas.

Graduate and medical students, postdoctoral fellows, and physicians in training who do not yet meet the above qualifications for active or corresponding membership should apply for **associate** membership. Forms for associate membership are available from the AACR Office.

PROCEDURES FOR APPLICATION

There are three deadlines for the receipt of a membership application: January 1, May 1, and September 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all members. The same procedure is followed by the Special Memberships Committee which receives applications for corresponding membership. Candidates will be notified according to the following schedule:

Receipt of Application in AACR Office

January 1
May 1
September 1

Notification of Candidate

March
July
November

A complete application consists of the following material:

1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate's most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate's achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical scientific standards. –OR– The nominator may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3 above from a seconder who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). –OR– The seconder may supply the responses requested at the bottom of the application form in the section entitled "STATEMENT OF SUPPORT" (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author. As noted above, evidence of patents developed by the candidate may be submitted in lieu of one or both of the publications. If submitting patents, supply patent number and year awarded.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
FAX: 215/440-9313

RESPONSIBILITIES OF MEMBERSHIP

Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues. In 1996 annual dues for active members are \$160, \$95 of which is designated for AACR journal subscriptions. Newly elected members of the AACR who have already purchased subscriptions to *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, or *Cancer Epidemiology, Biomarkers & Prevention* at the higher, nonmember rates will receive reimbursement of the unused portion of those subscriptions once their first year's membership dues are paid in full.

Corresponding members are required to pay dues (\$80 in 1996) and may, if they wish, subscribe to *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, or *Cancer Epidemiology, Biomarkers & Prevention* at reduced member rates.

Applicants elected in March will be responsible for payment of that year's dues; applicants elected in July and November will pay dues for the following year. Applicants elected in March and July will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in November.

Margaret Foti, Ph.D.
Executive Director

AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.

Public Ledger Building • Suite 816 • 150 S. Independence Mall West • Philadelphia, PA 19106-3483



APPLICATION FOR ACTIVE OR CORRESPONDING MEMBERSHIP

NAME OF CANDIDATE: _____ DATE OF BIRTH: _____
LAST FIRST M.I.

PRESENT POSITION/TITLE: _____

INSTITUTIONAL AFFILIATION: _____

INSTITUTIONAL ADDRESS: _____

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER: _____ FAX NUMBER: _____

E-MAIL NUMBER (CARRIER): _____

PRIMARY FIELD OF RESEARCH (Please check only one):

<input type="checkbox"/> Biochemistry and Biophysics	<input type="checkbox"/> Biostatistics	<input type="checkbox"/> Carcinogenesis
<input type="checkbox"/> Cellular Biology and Genetics	<input type="checkbox"/> Clinical Investigations	<input type="checkbox"/> Endocrinology
<input type="checkbox"/> Epidemiology	<input type="checkbox"/> Immunology	<input type="checkbox"/> Molecular Biology and Genetics
<input type="checkbox"/> Preclinical Pharmacology and Experimental Therapeutics	<input type="checkbox"/> Virology	<input type="checkbox"/> Other: _____ (Please specify)

ACADEMIC DEGREES (Including where and when granted)

EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list most recent first)

PUBLICATIONS (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If submitting patents, supply patent number and year awarded.)

CANDIDATE
NOMINATED BY*: _____
(Please print)

CANDIDATE
SECONDED BY*: _____
(Please print)

CANDIDATE IS APPLYING FOR (Check one): ☐ ACTIVE ☐ CORRESPONDING MEMBERSHIP

STATEMENT OF SUPPORT

Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

How long has the candidate worked in the field of cancer research? _____ years

Will the candidate make a long-term contribution to cancer research? ____Yes ____No

Does the candidate's research adhere to accepted ethical standards? ____Yes ____No

I therefore recommend this candidate for membership in the American Association for Cancer Research.

How long has the candidate worked in the field of cancer research? _____ years

Will the candidate make a long-term contribution to cancer research? ____Yes ____No

Does the candidate's research adhere to accepted ethical standards? ____Yes ____No

I therefore recommend this candidate for membership in the American Association for Cancer Research.

Signature of nominator* _____ Date _____ Signature of seconder* _____ Date _____

See Guidelines for Application on the reverse side of this form for further instructions.

*Both nominator and seconder must be active, corresponding, emeritus, or honorary members of the AACR.



AMERICAN ASSOCIATION FOR CANCER RESEARCH

GUIDELINES FOR APPLICATION FOR ASSOCIATE MEMBERSHIP

QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who are following a course of study or who are working in a research program relevant to cancer. Scientists in training who already have a substantial record of publications may wish to apply for active or corresponding membership which confers full benefits of membership.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Associate members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a paper for presentation at the AACR annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, corresponding, emeritus, or honorary member in good standing of the AACR also signs the abstract of the paper in support of the work (In this instance, the member who cosigns the abstract does not lose his or her own sponsorship privilege.);
2. an advance copy of the scientific Program and (if one has been purchased by the associate member) the *Proceedings of the American Association for Cancer Research* which contains abstracts of all papers being presented at each annual meeting;
3. the privilege of registering for the annual meeting at the low student rate (This rate is otherwise available only to predoctoral students.);
4. preferred access to the AACR Employment Register;
5. optional subscriptions to the Association's high-quality journals *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, and *Cancer Epidemiology, Biomarkers & Prevention* at reduced member rates;
6. priority notification of events in the AACR's series of special conferences on timely subjects in the field;
7. reduced registration rates at special conferences;
8. the receipt of AACR newsletters, meeting announcements, and an up-to-date membership directory; and
9. the facilitation of informal scientific exchange with leading researchers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the AACR. Three completed copies of the form should be submitted; at least one of these copies must carry the original signatures of both the candidate

and the nominator. The application form may be submitted to the Association Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check for one year's dues payment must accompany the application. Dues are currently \$35 for associate members residing in the Americas and \$45 for residents of other countries. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the \$35 or \$45 dues payment to:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
215/440-9300

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AACR Board of Directors. Dues for 1995 and 1996 have been set at \$35 per year for residents of the Americas and \$45 for residents of other countries. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in November 1995 for the forthcoming annual meeting must have paid dues for 1995. Any newly elected associate members of the AACR who have already purchased subscriptions to *Cancer Research*, *Clinical Cancer Research*, *Cell Growth & Differentiation*, or *Cancer Epidemiology, Biomarkers & Prevention* at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member's subscription.

Each Fall the AACR will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member's current registrar, dean, or department head, verifying the member's current academic status. The Association's By-Laws state that dues are payable for each year in advance by January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1995 may retain associate membership until December 31, 1999. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti, Ph.D.
Executive Director

AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.

Public Ledger Building • Suite 816 • 150 S. Independence Mall West • Philadelphia, PA 19106-3483



APPLICATION FOR ASSOCIATE MEMBERSHIP

NAME OF CANDIDATE: _____ DATE OF BIRTH: _____
LAST FIRST M.I.

INSTITUTIONAL AFFILIATION: _____

INSTITUTIONAL ADDRESS: _____

(City) (State/Province) (Country) (Postal Code)

TELEPHONE NUMBER: _____ FAX NUMBER: _____

PRESENT ACADEMIC STATUS/TITLE (Please check only one): E-MAIL NUMBER (CARRIER): _____

____ Graduate Student ____ Medical Student
____ Physician in Training ____ Postdoctoral Fellow

PRIMARY FIELD OF RESEARCH (Please check only one):

____ Biochemistry and Biophysics ____ Biostatistics ____ Carcinogenesis
____ Cellular Biology and Genetics ____ Clinical Investigations ____ Endocrinology
____ Epidemiology ____ Immunology ____ Molecular Biology and Genetics
____ Preclinical Pharmacology and ____ Virology ____ Other: _____
Experimental Therapeutics (Please specify)

ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide information on degree currently being sought and the anticipated date of completion of this degree program.)

RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)

PUBLICATIONS (List the authors, title, journal, volume, inclusive pages, and year of any article in a peer-reviewed journal on which the candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)

CANDIDATE NOMINATED BY: _____
(Please type or print name of AACR member* in good standing.)

SIGNATURES

I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverse side of this form, and I understand the privileges and responsibilities of this class of membership. I certify that the statements on this application are true.

Signature of Candidate: _____ Date: _____

I recommend this candidate for associate membership in the American Association for Cancer Research. To the best of my knowledge, the candidate is qualified for this class of membership, and the statements on this application are true.

Signature of Nominator*: _____ Date: _____

Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator. Enclose a check in U.S. funds, made payable to AACR, Inc., and drawn on a U.S. bank for one year's dues. Dues are currently \$35 for associate members residing in the Americas and \$45 for residents of other countries.

Check one of the following boxes only if this form is being submitted between September 1 and December 31:

The enclosed dues payment should be applied to the ☐ current ☐ forthcoming calendar year.

(NOTE: If dues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will not be eligible to sponsor an abstract for presentation at the annual meeting in March on April of that year.) See Guidelines for Application on the reverse side of this form for further instructions.

*Nominator must be active, corresponding, emeritus, or honorary member of the AACR.

(This form may be reproduced.)



87th AACR Annual Meeting Preliminary Program

(All events take place in the Washington Convention Center, unless otherwise indicated.
Names of session chairpersons are underlined.)

SATURDAY, APRIL 20, 1996

- 11:00 a.m.-8:00 p.m. Registration**
- 12:00 noon-6:30 p.m. Educational Sessions (*Sessions are two hours in length. Exact schedule to be announced.*)**
- ED1** *Human Pharmacogenetics: Molecular Mechanisms and Clinical Relevance in Cancer Treatment*, William E. Evans, Denis M. Grant, Robert B. Diasio
- ED2** *Bench to Bedside: Opportunities and Pitfalls in the Discovery and Development of Cancer Therapies*, Robert L. Capizzi, Allen I. Oliff, Randall K. Johnson, Kenneth R. Harrap
- ED3** *The Cell Cycle*, Michael B. Kastan, William G. Kaelin, Jr., Chi Van Dang
- ED4** *Beyond the Human Genome Project: Technical Aspects of Genomic Characterization and Its Application to Cancer Research*, Glen A. Evans
- ED5** *Combinatorial Library Methods for Basic Research and Drug Discovery*, Sydney E. Salmon, Kit S. Lam, George Smith, Victor Krchnak
- ED6** *Transcriptional Regulatory Pathways and the Response to Cellular Stress*, Arnold B. Rabson, Carl Wu, Albert J. Fornace, Jr.
- 2:00 p.m.-6:00 p.m. Methods Workshops (*Separate registration required*)**
- WK1** *Quantitative Biology and Pharmacodynamics*, Robert C. Jackson, Robert L. Dedrick, Mark J. Ratain, William R. Greco
- WK2** *Animal Models: Transgenic and Knockout Mice in Cancer Investigations*, Terry A. Van Dyke, Lawrence A. Donehower, Beverly Koller, Earl Ruley
- 6:30 p.m.-8:30 p.m. Women in Cancer Research Guest Lecture and Reception.** Washington, DC
Renaissance Hotel
- 8:00 p.m.-10:00 p.m. Opening Mixer.** Washington, DC
Renaissance Hotel

SUNDAY, APRIL 21, 1996

- 7:00 a.m.-4:00 p.m. Registration**
- 7:00 a.m.-8:00 a.m. Sunrise Sessions**
- SUN1** **Diane F. Birt:** Mechanisms of Dietary Prevention of Cancer
- SUN2** **William S. Dalton:** Challenges in Bone Marrow Transplantation
- SUN3** **Ronald B. Herberman:** Natural Killer Cells
- SUN4** **Rakesh K. Jain:** Tumor Pathophysiology: Role in Delivery of Molecules, Particles, and Cells
- SUN5** **Lovell A. Jones:** Estrogens and Breast Cancer
- SUN6** **Stanley J. Korsmeyer:** Apoptosis: Regulation and Oncogenesis
- SUN7** **Funmi I. Olopade:** Chromosomal Deletions and Cancer: Recent Advances in Mapping Techniques
- 7:00 a.m.-8:00 a.m. State Legislative Committees Meeting.**
Grand Hyatt Washington Hotel
- 8:00 a.m.-12:00 noon Poster Discussion Sessions**
- IM1** Antigenes, Vaccines, and Monoclonal Antibodies
- EN1** Breast Cancer I
- MB1** Gene Expression in Breast Cancer I

- 8:00 a.m.-12:00 noon Poster Sessions**
- MB2** Viral Oncogenesis I
- MB3** Transcription Factors
- MB4** Lung and Skin Cancer
- ET2** Pharmacokinetics and Toxicology
- ET3** Reversal of P-Glycoprotein Resistance by Small Molecules
- ET4** Gene Therapy I - Tumor Directed Therapies
- ET5** Genetic Determinants of Chemosensitivity
- IM2** Cytokines and Tumor Immunity I
- EN2** Prostate Cancer I
- CI2** Supportive Care and Tumor Biology
- CG2** Chemical Carcinogenesis
- CG3** Genetic and Cytogenetic Alterations in Human Tumor Cells
- BL2** Invasion and Motility
- BL3** Genetic Changes and Altered Gene Expression During Tumor Progression
- EP1** Genetic Epidemiology - Prevention and Susceptibility
- EP2** Retinoids, Antioxidants, and NSAIDS
- 8:15 a.m.-11:45 a.m. Minisymposia**
- CI1** Leukemia and Lymphoma
- CG1** Biomarkers of Chemical Exposure
- ET1** DNA Topoisomerase I and Camptothecins
- BL1** Mechanisms of Apoptosis
- 8:15 a.m.-11:30 a.m. Plenary Session**
The Progress and Promise of Cancer Research: A Celebration of the Twenty-fifth Anniversary of the National Cancer Act, Joseph R. Bertino, Harold E. Varmus, Arnold J. Levine, Susan Band Horwitz, Lloyd J. Old, Paul Talalay, James F. Holland
- 11:45 a.m.-12:45 p.m. 35th Clowes Award Lecture**
Robert A. Weinberg, *Control of Proliferation by the Cell Cycle Clock*
- 12:30 p.m.-5:00 p.m. Commercial Exhibit Show**
- 1:00 p.m.-2:00 p.m. Controversy Session 1**
Are Antioxidants Useful in Cancer Prevention?, Waun Ki Hong, Frank L. Meyskens, Jr., E. Robert Greenberg
- 1:00 p.m.-2:00 p.m. Controversy Session 2**
Have Preclinical Models In Studies of Drug Resistance Provided Accurate Predictions for Clinicians?, Bruce A. Chabner, Susan E. Bates, Herbert M. Pinedo
- 1:00 p.m.-5:00 p.m. Poster Discussion Sessions**
- BL4** Genes Involved in Invasion and Metastasis
- ET7** DNA Repair and Its Inhibition
- CG4** Oxygen Radicals
- 1:00 p.m.-5:00 p.m. Poster Sessions**
- MB6** Signal Transduction
- MB7** Gene Regulation in Breast Cancer
- MB8** Gene Regulation
- ET8** Expression of Drug Resistance Genes in Human Tumors
- ET9** P-Glycoprotein, MRP, and Other Mechanisms of Multidrug Resistance
- ET10** *ras*/raf Directed Therapy
- ET11** Pyrimidine Antimetabolites
- IM3** Cytokines and Tumor Immunity II
- EN3** Growth Factors and Cell Surface Receptors
- CI4** Phase II/III Studies
- CG5** Animal Models
- BL5** Growth Factors and Cytokines
- BL6** Biological Aspects of Drug Resistance

BL7 Characterization of Cell Cycle Genes in Tumors and Cell Lines
RR1 Radiosensitivity/Hypoxia/Other Studies
EP3 Modulation of Carcinogenesis *in vivo*

1:45 p.m.-5:15 p.m. Minisymposia

CI3 Clinical Pharmacology I
ET6 New Drugs I
MB5 Telomerase I

2:15 p.m.-5:15 p.m. Symposia

S1 *Tumor Suppressor Genes.* Bert Vogelstein, Yosef Shiloh, Todd Waldman, Alexander Kamb, Allan Bradley, Richard D. Klausner
S2 *Ovarian Cancer: From the Laboratory to the Clinic.* Robert F. Ozols, Thomas C. Hamilton, Donald M. Black, E.G. Elisabeth de Vries, David T. Curiel
S3 *Apoptosis: Manipulating Programmed Cell Death in Cancer.* David E. Fisher, Hermann Steller, Stanley J. Korsmeyer, Douglas R. Green, Douglas K. Miller
S4 *Monoclonal Antibodies: Clinical Effectiveness.* Ellen S. Vitetta, Mark Sliwkowski, Pamela A. Trail, Dana C. Matthews
S5 *Genetic, Environmental, and Behavioral Factors in Cancer Risk.* Organized by the AACR Minority Issues Committee. Lucile L. Adams-Campbell and Francis Ali-Osman, John S. Kovach, Ronald A. Morton, Jr., George E. Bonney, Margaret R. Spitz, Bailus Walker, Hie-Won L. Hann

5:30 p.m.-6:30 p.m. Joseph H. Burchenal AACR Clinical Research Award Lecture

6:30 p.m.-9:00 p.m. Minority Issues Committee Symposium.
Reflections from Scientists: Their Pathways to Success. Marian Johnson-Thompson, Tracie Bunton, Cesar Calderon, Jerrel Yakel, Ricardo J. Parker, Harold Amos. *Washington, DC Renaissance Hotel*

8:00 p.m.-10:30 p.m. Annual Reception. *Grand Hyatt Washington Hotel*

MONDAY, APRIL 22, 1996

7:00 a.m.-4:00 p.m. Registration

7:00 a.m.-8:00 a.m. Sunrise Sessions

SUN8 **Peggy J. Farnham:** Nuclear Oncogenes: Effects on Cell Cycle Regulation and Neoplastic Transformation
SUN9 **John G. Gribben:** Quantitative PCR as a Tool to Detect Minimal Residual Disease in Leukemia and Lymphoma
SUN10 **Stephen S. Hecht:** Chemoprevention of Cancers Associated with Tobacco Use
SUN11 **V. Craig Jordan:** Antiestrogens
SUN12 **Philip Livingston:** Specific Immunotherapy of Melanoma
SUN13 **John A. McLachlan:** Environmental Carcinogens: Their Impact in Cancer
SUN14 **Daniel Medina:** Multistage Mammary Carcinogenesis

7:00 a.m.-8:00 a.m. WICR Networking Session. *Washington, DC Renaissance Hotel*

8:00 a.m.-11:00 a.m. Symposia

S6 *Steroid Hormones: Breast and Prostate Cancer.* Myles A. Brown, Benita S. Katzenellenbogen, Donald P. McDonnell, Norman M. Greenberg, Roger L. Miesfeld
S7 *Matrix Metalloproteinases and Their Inhibitors.* Lynn M. Matrisian, Ruth J. Muschel, Motoharu Seiki, Yves DeClerck, Peter Brown

S8 *Recent Developments in Gene Therapy.* Drew M. Pardoll, Inder M. Verma, Philip D. Greenberg, Arthur Bank
S9 *Viral Mechanisms of Carcinogenesis.* Harald zur Hausen, David M. Livingston, William Robinson, Yuan Chang, Kathleen R. Cho

8:00 a.m.-12:00 noon Poster Discussion Sessions

BL8 Apoptosis
MB9 DNA Repair
ET13 Biology of MRP

8:00 a.m.-12:00 noon Poster Sessions

BL9 Tumor Vasculature and Angiogenesis
BL10 Differentiation and Growth Inhibition
BL11 Regulation and Characterization of Cell Cycle Genes
IM5 Immunobiology
EN4 Nuclear Receptors and Signal Transduction
CI5 Clinical Pharmacology II
CG6 Molecular Responses to DNA Damage
CG7 Cell Culture and Animal Models
EP5 Cancer Biomarkers
ET14 Novel Topoisomerase Inhibitors
ET15 Kinase Directed Therapies
ET16 Novel Antitumor Agents I
ET17 Novel Antitumor Agents II
MB10 p53
MB11 Oncogenes I
MB12 Gene Expression I

8:15 a.m.-11:45 a.m. Minisymposia

EP4 Mechanisms of Chemoprevention
IM4 Tumor Antigens and Effector Cell Response
ET12 Novel Drug Resistance Mechanisms
RR2 Radiation, Apoptosis, and the Cell Cycle

10:00 a.m.-4:00 p.m. Commercial Exhibit Show

11:30 a.m.-12:45 p.m. Presidential Address

Joseph R. Bertino. *The Evolution in Concepts of Drug Resistance: Implications for the Evaluation of New Drugs*
Presentation of Fourth Gertrude Elion Cancer Research Award

1:00 p.m.-2:00 p.m. Fifth American Cancer Society Award Lecture

Lee W. Wattenberg. *Prevention of Cancer: The Role of Chemoprevention for the General Population and for Individuals at High Risk Due to Genetic Defects or Other Factors*

1:00 p.m.-2:00 p.m. Controversy Session 3

Does Regional Chemotherapy Work? David S. Alberts, Maurie Markman, Michael J. O'Connell

1:00 p.m.-5:00 p.m. Poster Discussion Sessions

CG8 Carcinogen Metabolism in Animals and Humans
BL13 Molecular Effectors of Tumor Progression
ET18 Antifolate and Thymidylate Synthase Inhibitors

1:00 p.m.-5:00 p.m. Poster Sessions

BL14 Antiinvasion or Metastasis Strategies
BL15 Behavior of Naturally Occurring Tumors and Model Systems
IM6 Immunomodulation
IM7 Modulation of T Cell Function
IM8 Modulation of Macrophage and NK/LAK Cell Function
CI7 Clinical Pharmacology - Pharmacokinetics
CG9 Metabolism and Activation of Carcinogens in Animal Models
CG10 Tumor Promotion/Progression
EN6 Breast Cancer II
ET19 Alkylating Agents and Platinum Analogs I

ET20 DNA-Active Agents
ET21 DNA Topoisomerase I Inhibitors
ET22 DNA Topoisomerase II and Inhibitors
MB14 Genetic Instability
MB15 Lipid Metabolism
MB16 Gene Expression II

1:45 p.m.-5:15 p.m. Minisymposia

EN5 Retinoid Action
MB13 Cellular and Viral Oncogenes
BL12 Cell Cycle Genes in Cancer
CI6 Minimal Residual Disease and Predictors of Outcome in Solid Tumors

2:15 p.m.-5:15 p.m. Symposia

S10 *Cell Responses to DNA Damaging Agents.* Nathan A. Berger, Mark T. Muller, Joseph Avruch, George R. Stark, William F. Morgan
S11 *Drug Resistant Genes: Transcriptional and Translational Mechanisms.* Kathleen W. Scotto, Jane Clifford Azizkhan, Jim A. Wright, Edward Chu, Ian D. Hickson
S12 *Melanoma as a Clinical Model.* Alan N. Houghton, Jane W. Fountain, Steven A. Rosenberg, Pierre van der Bruggen, John M. Kirkwood
S13 *Nutrition and Cancer.* Walter C. Willett, David J. Hunter, John D. Potter, Diane F. Birt, Frank L. Meyskens, Jr.

5:30 p.m.-6:00 p.m. Presentation by NCI Director: Richard D. Klausner

6:00 p.m.-7:00 p.m. Business Meeting of Members

7:00 p.m.-8:30 p.m. NCI Training Branch Session. Washington, DC Renaissance Hotel

TUESDAY, APRIL 23, 1996

7:00 a.m.-4:00 p.m. Registration

7:00 a.m.-8:00 a.m. Sunrise Sessions

SUN15 **Robert L. Comis:** Lung Cancer: A Primer
SUN16 **Jerry D. Glickson:** NMR As a Prognosticator of Tumor Therapeutic Response
SUN17 **Susan Jakcn:** Protein Kinase C in Carcinogenesis
SUN18 **Jay A. Levy:** Immunological Features of AIDS Pathogenesis
SUN19 **Yves G. Pommier:** DNA Topoisomerases and Their Inhibitors
SUN20 **Barrett J. Rollins:** Chemokines and Leukocyte-specific Chemotactic and Activating Factors
SUN21 **Stephen E. Sallan:** Childhood Leukemias: The Latest in Treatment

7:00 a.m.-8:00 a.m. NIH Grants Session. Grand Hyatt Washington Hotel

8:00 a.m.-11:00 a.m. Symposia

S14 *Endogenous DNA Damage: Detection and Biological Significance.* John M. Essigmann, Leona D. Samson, B. Singer, Lawrence J. Marnett, Lawrence A. Loeb
S15 *Targeting Growth Factor Receptors for Therapy.* John Mendelsohn, Thomas A. Waldmann, David W. Golde, Ira Pastan, Alexander Levitzki
S16 *Aberrant Transcription Factors and Malignancy.* Lorraine J. Gudas, A. Thomas Look, Anne Dejean, Christopher T. Denny, Terry H. Rabbitts
S17 *Thymidylate Synthase and Its Inhibitors.* Frank Maley, Carmen Allegra, Gary K. Smith, William R. Montfort, Bruce J. Dolnick

8:00 a.m.-12:00 noon Poster Discussion Sessions

BL17 Signal Transduction I
CI8 Markers of Response and Predictors of Outcome in Solid Tumors
ET24 New Approaches to Drug Discovery and Selective Therapeutics

8:00 a.m.-12:00 noon Poster Sessions

ET25 Purine and Pyrimidine Antagonists
ET26 Combination Chemotherapy
ET27 Tubulin Inhibitors
ET28 Chemoprevention Therapeutics and Other Antitumor Agents
MB18 Telomerase II
MB19 Gene Amplification and Chromosome Mapping
MB20 Oncogenes II
EP7 Mechanisms of Chemoprevention by Endogenous and Dietary Factors
IM9 Gene Therapy
EN7 Hormonal Carcinogenesis and Hormonal Control of Cell Growth and Death
BL18 Apoptosis - Molecular Mechanisms I
BL19 Kinetics, Models (Cell Growth and Death)
CG11 Metabolism and Activation of Carcinogens in Humans
CG12 Genetic Susceptibility and Premalignant Lesions in Humans
CI9 Phase I and II Clinical Trials
CI10 Clinical Biology of Solid Tumors

8:15 a.m.-11:45 a.m. Minisymposia

EP6 Genetic Epidemiology: Genetic Susceptibility and Gene-environmental Interaction
ET23 Resistance to Platinum Drugs
MB17 Tumor Suppressor Genes I
BL16 Host Effects on Tumor Cells: Angiogenesis

11:00 a.m.-5:00 p.m. Commercial Exhibit Show

11:45 a.m.-12:45 p.m. 20th Rosenthal Award Lecture

James O. Armitage. *The Place of Bone Marrow Transplantation in the Management of Patients with Lymphoma*

1:00 p.m.-2:00 p.m. Late-breaking Research Session

1:00 p.m.-5:00 p.m. Poster Discussion Sessions

CI11 Biology of Breast Cancer
ET30 P-Glycoprotein: Structure/Function Studies
MB21 Prostate Cancer

1:00 p.m.-5:00 p.m. Poster Sessions

ET31 Ribozyme and Antisense Gene Therapy Strategies
ET32 Chimeric Toxins and Enzyme-derived Therapies
ET33 Antifolates
ET34 Lipid Ethers and Other Lipid Antitumor Agents
MB22 Gene Expression in Breast Cancer II
MB23 DNA Repair and Methylation
MB24 Tumor Suppressor Genes II
EP8 Genetic Susceptibility/Gene-environmental Interactions/Other Epidemiological Studies
IM11 Melanoma Associated Antigens and Effector Cell Response
IM12 Antigens, Vaccines, and Effector Cell Responses
BL21 Proteases: Their Role in Metastasis and Invasion
BL22 Adhesion
BL23 Effect of Carbohydrates on Metastasis and Invasion, Adhesion and Proteases
CG14 Altered Gene Expression in Carcinogenesis
RR3 p53/Radioimmunotherapy/Phototherapy
CI12 Clinical Tumor Biology I

1:45 p.m.-5:15 p.m. Minisymposia

IM10 Cytokines and Effector Cells
ET29 Epidermal Growth Factor Receptor Directed Therapeutics
CG13 Carcinogen-DNA Adducts: Influence on Transcription and Replication
BL20 Invasion and Metastasis

- 2:15 p.m.-5:15 p.m. Symposia**
- S18** *Cell Signaling*, Channing Der and Deborah Morrison, Andrius Kazlauskas, Ann Marie Pendergast, Melanie Cobb
- S19** *Cancer Chemoprevention in Humans*, Thomas W. Kensler, Gary J. Kelloff, Michael N. Gould, Alberto F. Costa, Francis M. Giardiello
- S20** *Neuroblastoma: Recent Advances in Biology and Treatment*, Garrett M. Brodeur, Susan L. Cohn, Nai-Kong V. Cheung, C. Patrick Reynolds, Katherine K. Matthay, Robert P. Castleberry
- S21** *Telomerase, Cell Senescence, and Cancer*, Calvin B. Harley, Jerry W. Shay, J. Carl Barrett, Maria A. Blasco, Karen Prowse

4:45 p.m.-5:30 p.m. DeWitt S. Goodman Lecture
David J. Mangelsdorf, *Retinoid X Receptors: Master Regulators of Nuclear Hormone Receptor Signaling*

5:30 p.m.-6:30 p.m. 15th Rhoads Award Lecture
Carol W. Greider, *Telomerase Structure and Function in Normal Cells and in Cancer*

6:30 p.m.-8:00 p.m. WICR Business Meeting, Washington, DC
Renaissance Hotel

WEDNESDAY, APRIL 24, 1996

7:00 a.m.-2:00 p.m. Registration

7:00 a.m.-8:00 a.m. Sunrise Sessions

- SUN22** **Ernest C. Borden**: Interferons in Cancer
- SUN23** **Richard A. Heyman**: Transcription Factors As Therapeutic Targets
- SUN24** **Theodore S. Lawrence**: Radiation Sensitization
- SUN25** **Eric K. Rowinsky**: Drugs Which Interact with Microtubules: An Update
- SUN26** **Jeffrey Schlom**: Tumor Vaccines
- SUN27** **Peter D. Senter**: Prodrugs for Cancer Chemotherapy
- SUN28** **Martha R. Stampfer**: Culturing Normal and Transformed Human Epithelial Cells

8:00 a.m.-11:00 a.m. Symposia

- S22** *Cell Adhesion Receptors and the Cytoskeleton*, Jun-Lin Guan and Rudolph L. Juliano, Thomas P. Stossel, Paul Polakis, Eva Ann Turley
- S23** *Drug Metabolizing Enzymes in Cancer Prevention and Therapy*, Cecil B. Pickett, F. Peter Guengerich, Frank J. Gonzalez, Chung S. Yang
- S24** *The Cell Cycle and Damage Response Pathways: Potential Targets for Therapy*, Stephen H. Friend, Frank McCormick, David Beach, James M. Roberts, Nick J. Dyson, Paul A. Marks

8:00 a.m.-12:00 noon Poster Discussion Sessions

- EP9** Mutation Epidemiology and Biomarkers of Environmental Exposure
- ET36** Therapy Directed Apoptosis
- IM13** Cytokines and Tumor Immunity III

8:00 a.m.-12:00 noon Poster Sessions

- EN8** Hormone Action, Hormone Synthesis, Metabolism, and Inhibitors
- BL24** Apoptosis - Molecular Mechanisms II
- BL25** Regulation of Cell Cycle Genes by Endogenous and Exogenous Factors
- BL26** Extracellular Matrix, Signaling, and Adhesion
- CG16** DNA Adducts
- CG17** Exposure Biomarkers
- CI14** Clinical Tumor Biology II
- EP10** Effects of Chemopreventive Agents on Carcinogen Metabolism and DNA Adducts

- IM14** Monoclonal Antibodies: Immunoconjugates and Immunotherapy
- MB26** Techniques in Molecular Biology
- MB27** Enzymes and Isoenzymes
- MB28** Gene Expression in Ovarian Cancer
- ET37** Taxol
- ET38** Gene Therapy II - Gene Transfer, Cell Cycle, and Other Studies
- ET39** Pharmacodynamics
- ET40** Glutathione and Other Drug Resistance Mechanisms

8:15 a.m.-11:45 a.m. Minisymposia

- CI13** Phase I Trials
- CG15** Signal Transduction in Tumor Progression
- ET35** Human Gene Therapy: Early Trial Results and Promising New Leads
- MB25** Microsatellite Instability

11:45 a.m.-12:45 p.m. 15th Cain Award Lecture
Kurt W. Kohn, *Beyond DNA Crosslinking*

1:00 p.m.-2:00 p.m. Controversy Session 4

Is p53/Rb Important for Therapeutic Outcome?, William F. Benedict, Carlos Cordon-Cardo, David Sidransky

Controversy Session 5

Should Genetic Testing Be Done on Patients to Assess Cancer Risk?
Judy E. Garber

1:00 p.m.-5:00 p.m. Poster Discussion Sessions

- EP11** Diet and Nutrition
- ET42** Developing Effective Gene Therapy: Promising Strategies and Vectors
- MB29** Retinoids and Differentiation

1:00 p.m.-5:00 p.m. Poster Sessions

- EN10** Gynecological, Lung, and Genitourinary Cancers
- RR4** Animal and Patient Studies with Radiation/Drug-Radiation Studies
- BL28** Apoptosis - Clinical Implications
- BL29** Signal Transduction II
- CG18** Mutagenesis and Repair
- CG19** Growth Factors and Signaling in Carcinogenesis
- CI16** Clinical Tumor Biology III
- IM15** Monoclonal Antibodies; Immunotoxins and Immunotherapy
- MB30** Tumor Suppressor Genes III
- MB31** Tumor Suppressor Genes IV
- MB32** Gene Regulation and Expression
- ET43** Regulation of P-Glycoprotein Expression
- ET44** New Drugs II
- ET45** Tumor Models and Methods of Drug Delivery
- ET46** Liposomes and Drug Delivery Formulations
- ET47** Experimental Drug Resistance

1:45 p.m.-5:15 p.m. Minisymposia

- BL27** Novel Signaling Pathways and Crosstalk
- CI15** Predictors of Response and Prognosis Markers in Solid Tumors
- EN9** Prostate Cancer II
- ET41** Alkylating Agents and Platinum Analogs II

2:15 p.m.-5:15 p.m. Symposia

- S25** *Tumor Angiogenesis*, Judah Folkman and Mark A. Goldberg, Webster K. Cavenee, Richard I. Weiner, Philip E. Thorpe, Elise C. Kohn
- S26** *Genetic Predisposition to Cancer*, Mark H. Skolnick, Francis S. Collins, Richard D. Kolodner, William B. Isaacs, Sean Tavtigian

ADVANCE REGISTRATION FORM

AMERICAN ASSOCIATION FOR CANCER RESEARCH 87TH ANNUAL MEETING - WASHINGTON, DC - April 20-24, 1996

Return to
American Association for Cancer Research • Public Ledger Building, Suite 816
150 S. Independence Mall West • Philadelphia, PA 19106-3483 • FAX: 215-440-7228

- DEADLINES:**
- **March 1, 1996** for reduced rates and to ensure receipt of meeting materials by mail in late March or early April
 - **March 25, 1996** for all registration by mail (*Registration forms received after this date will not be accepted.*
Registration will be conducted at the Washington Convention Center from April 20-24.)
 - **April 17, 1996** to cancel registration and receive refund less cancellation fee (\$35)

(Please print)

NAME: _____
Last First/Middle Initial AACR Member Number

TITLE: _____ ADDRESS: _____
Institution

Street, Building, or Post Office Box

City State or Province Zip/Postal Code Country (if not U.S.)

TELEPHONE NO.: _____ FAX NO.: _____

☐ Check this box if you have a physical disability and have special requirements for transportation, hotel accommodations, or other facilities in connection with the meeting. A member of the Association Staff will contact you.

WHAT IS YOUR PRIMARY FIELD OF RESEARCH (Please check only one):

- ☐ ¹Biochemistry and Biophysics ☐ ²Carcinogenesis ☐ ³Cellular Biology & Genetics ☐ ⁴Clinical Investigations
☐ ⁵Endocrinology ☐ ⁶Epidemiology ☐ ⁷Experimental Therapeutics ☐ ⁸Immunology ☐ ⁹Molecular Biology & Genetics
☐ ¹⁰Prevention ☐ ¹¹Radiobiology/Radiation Oncology ☐ ¹²Virology ☐ ¹³Other (please specify): _____

ARE YOU THE PRESENTER OF AN ABSTRACT SUBMITTED FOR THE 1996 AACR MEETING? ☐ Yes ☐ No

ON WHICH DAYS WILL YOU ATTEND THE 1996 AACR ANNUAL MEETING?

- ☐ Saturday, April 20 ☐ Sunday, April 21 ☐ Monday, April 22 ☐ Tuesday, April 23 ☐ Wednesday, April 24

PAYMENT OF REGISTRATION

Fees may be paid by check or with a MasterCard, VISA, American Express, or Eurocard account. All payments must be made in U.S. currency, and all checks must be drawn on a U.S. bank. Payment must accompany this form; purchase orders will not be accepted as payment.

	On or Before March 1	After March 1
<input type="checkbox"/> Active/Corresponding Member Rate	\$135	\$170
<input type="checkbox"/> Nonmember Rate (includes copy of AACR <i>Proceedings</i>)	\$270	\$340
<input type="checkbox"/> Emeritus Member Rate	\$ 50	\$ 50
<input type="checkbox"/> Associate Member Rate ^a	\$ 75	\$ 85
<input type="checkbox"/> Predoctoral Student Rate ^b	\$ 60	\$ 70
<input type="checkbox"/> Honorary Member Rate	\$ 0	\$ 0
<input type="checkbox"/> AACR <i>Proceedings</i> ^c	\$ 35 Members \$ 45 Nonmembers	\$ 35 Members \$ 45 Nonmembers
<input type="checkbox"/> Optional Overseas Surcharge ^d	\$ 25	N.A.
<input type="checkbox"/> <i>Proceedings</i> on CD-ROM	\$ 35 Members \$ 45 Nonmembers	\$ 35 Members \$ 45 Nonmembers
<input type="checkbox"/> Methods Workshop Registration	\$ 50 Members \$ 75 Nonmembers	\$ 50 Members \$ 75 Nonmembers

TOTAL ENCLOSED OR CHARGED \$ _____ \$ _____

METHOD OF PAYMENT

- ☐ Check payable to AACR, Inc. in U.S. currency, drawn on a U.S. bank

Person/Institution Issuing Check Check No.

☐ MasterCard ☐ VISA ☐ American Express ☐ Eurocard

Card Number Expiration Date

Signature

^aAn application for Associate Membership may accompany this form, but these should be submitted well before the March 1 deadline, as review of the Associate Membership application may delay registration.

^bStudents must enclose a statement, signed by the registrar, dean, or department head of their university or college on official letterhead, confirming their status. **Postdoctoral fellows or physicians in training do not qualify for the student registration rate.**

^cAACR members with paid-up subscriptions to an AACR journal and registrants who pay the nonmember fee receive the *Proceedings* automatically. If these members or nonmembers check this box and pay the fee, they will receive an additional copy of the *Proceedings*.

^dOptional payment for registrants outside of the U.S. and Canada only. Registrants paying this surcharge will receive meeting publications via airmail--printed matter before the annual meeting. This service not available after March 1.

AACR members in good standing will receive copies of the Program and *Proceedings* prior to the meeting. Nonmember and student registrants who meet the March 1 deadline will also receive the Program and (if they have purchased it) the *Proceedings* prior to the meeting. Nonmembers and students who do not meet the deadline must pick up publications at the meeting site.

REFUND POLICY

Refunds on registration fees will be granted on written request received in the AACR Office by April 17, 1996. Requests received after this date will not be honored. Receipts and badges (if they have been mailed) must be returned to the AACR Office with the refund request. A cancellation fee of \$35 will be deducted from all refunds to cover administrative costs.

(This form may be reproduced.)



**LATE-BREAKING RESEARCH SESSION
AT THE AACR ANNUAL MEETING
Tuesday, April 23, 1996**

One hour has been set aside for the presentation of about 4 definitive reports of highly significant and timely findings in the field. Criteria for the selection of these presentations and instructions for submission of abstracts are as follows:

INSTRUCTIONS FOR SUBMISSION OF LATE-BREAKING ABSTRACTS

1. The work to be presented must be of major novelty and significance, *e.g.*, the characterization of a new gene in familial cancer, and should not have been previously published in a peer-reviewed scientific journal or presented at a national meeting.
2. The abstract must be sponsored by an AACR member in good standing (dues paid for 1996).
3. Each member in good standing may sponsor only **one** abstract for this session whether or not he or she sponsored an abstract last December for the regular annual meeting program. If an associate member is the **sponsor**, the abstract must also be **endorsed** by an active or corresponding member in good standing. In this case, the **endorser** does **not** forfeit the opportunity to **sponsor** a late-breaking abstract.
4. Abstracts must be typed on **one** side of **one** sheet of white paper.
5. All text on the page must fit within an area 6 1/2" wide and 9" high (16.5 cm X 22.9 cm) with margins of at least 1" (2.5 cm) on the top, bottom, and sides of the page.
6. Each abstract must be accompanied by a covering letter from the sponsor explaining why the work is novel and significant enough to be considered for this late-breaking research session and certifying that the findings became available **after** the annual meeting abstract deadline of December 1, 1995. This letter must contain the sponsor's complete mailing address, FAX number, and Email address (if available) so that we can communicate the scheduling decision of the Program Committee.
7. Abstracts and covering letters must be received in the AACR Office by 5:00 p.m. Eastern Time on **March 15, 1996**. FAX transmissions are **not** acceptable. Carrying envelopes should be clearly marked "Late-Breaking Abstract," and should be addressed to American Association for Cancer Research, Public Ledger Building, Suite 816, 150 South Independence Mall West, Philadelphia, PA 19106-3483. If you wish to receive acknowledgment of receipt of your abstract, enclose a self-addressed post card with appropriate postage affixed. Accepted abstracts will not be published since they will be received after the *Proceedings of the American Association for Cancer Research* has been printed; however, they will be distributed at the session in Washington.
8. A special subcommittee of the Program Committee appointed by President Joseph R. Bertino will select the papers to be presented. Presenters of accepted papers will be notified via FAX no later than **March 29, 1996**.

CARCINOGENESIS FROM ENVIRONMENTAL POLLUTION: ASSESSMENT OF HUMAN RISK AND STRATEGIES FOR PREVENTION

Joint Meeting Organized by the
American Association for Cancer Research (AACR)
and the **International Agency for Research on Cancer (IARC)**

With the Collaboration of the Hungarian Cancer Society



October 6-9, 1996
Hotel Gellért
Budapest, Hungary



CONFERENCE CHAIRPERSONS

Frederica Perera / New York, USA
Paul Kleihues / Lyon, France

PROGRAM COMMITTEE

Hans-Olov Adami / Uppsala, Sweden
J. Carl Barrett / Research Triangle Park, USA
Paolo Boffetta / Lyon, France
Edward Bresnick / Worcester, USA
Mieczysław R. Chorąży / Gliwice, Poland
Joseph F. Fraumeni, Jr. / Bethesda, USA

Waun Ki Hong / Houston, USA
Margaret L. Kripke / Houston, USA
Kenneth Olden / Research Triangle Park, USA
Alán Pintér / Budapest, Hungary
Manfred F. Rajewsky / Essen, Germany
David Zaridze / Moscow, Russia

SCIENTIFIC PROGRAM

Keynote Address

Curtis C. Harris / Bethesda, USA

Cancer Incidence and Etiology

Witold A. Zatoński / Warsaw, Poland
Frederica Perera / New York, USA
J. Carl Barrett / Research Triangle Park, USA
Helmut Bartsch / Heidelberg, Germany

Air, Water, Food, and Soil Contamination

Radim J. Šrám / Prague, Czech Republic
Joellen Lewtas / Research Triangle Park, USA
Wiesław Jedrychowski / Cracow, Poland
Olav Axelson / Linköping, Sweden

Ambient, Environmental, and Occupation Exposure and Cancer Risk

Mieczysław R. Chorąży / Gliwice, Poland
Alán Pintér / Budapest, Hungary
Kimmo Peltonen / Helsinki, Finland
Monica C. Hollstein / Heidelberg, Germany
Kari Hemminki / Stockholm, Sweden

Tobacco

Ivan Plesko / Bratislava, Slovakia
Barbara S. Hulka / Chapel Hill, USA
Paolo L. Vineis / Turin, Italy
Stephen S. Hecht / Valhalla, USA
Krystyna Frenkel / New York, USA
Bernadette Schoket / Budapest, Hungary

Strategies for Prevention

Waun Ki Hong / Houston, USA
I. Bernard Weinstein / New York, USA
Anna Tompa / Budapest, Hungary

Roundtable Discussion

Paul Kleihues / Lyon, France
Hans-Olov Adami / Uppsala, Sweden
Paolo Boffetta / Lyon, France
Edward Bresnick / Worcester, USA
Andrew E. Czeizel / Budapest, Hungary
Terri Damstra / Research Triangle Park, USA
Edith Olah / Budapest, Hungary
Kenneth Olden / Research Triangle Park, USA
Manfred F. Rajewsky / Essen, Germany
William A. Suk / Research Triangle Park, USA
David Zaridze / Moscow, Russia

Applicants are encouraged to submit abstracts for poster presentation.

Information and Application Forms

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
(215) 440-9300 (215) 440-9313 (FAX)
Email: aacr@aol.com



AMERICAN ASSOCIATION FOR CANCER RESEARCH SCIENTIFIC CONFERENCES

FEBRUARY 19-25, 1996

***Cancer Susceptibility Genes and
Molecular Carcinogenesis***

Chairpersons: Curtis C. Harris, Bethesda, MD;
Allan Balmain, Glasgow, Scotland; Kenneth
Olden, Research Triangle Park, NC
Keystone Resort, Keystone, CO

MARCH 1-5, 1996

Proteases and Protease Inhibitors

Chairpersons: Lynn M. Matrisian, Nashville, TN;
Bonnie F. Sloane, Detroit, MI
Marriott's Bay Point Resort, Panama City
Beach, FL

APRIL 20-24, 1996

87th Annual Meeting

Chairperson: Lorraine J. Gudas, New York, NY
Washington D.C. Convention Center,
Washington, D.C.

Abstract Deadline: December 1, 1995

JUNE 8-12, 1996

Inducible Genomic Responses

Chairpersons: William T. Beck, Memphis, TN;
John A. Hickman, Manchester, England;
Richard I. Morimoto, Evanston, IL
Skamania Lodge, Stevenson (Columbia River
Gorge), WA

OCTOBER 2-6, 1996

***Novel Approaches in Blood and
Marrow Transplantation***

Second Annual Meeting of the American Society
for Blood and Marrow Transplantation
Chairpersons: O. Michael Colvin, Durham, NC;
Bruce R. Blazar, Minneapolis, MN
Hotel Del Coronado, San Diego, CA

OCTOBER 6-9, 1996

***Carcinogenesis from Environmental
Pollution: Assessment of Human Risks
and Strategies for Prevention***

Joint Meeting with International Agency for
Research on Cancer
Chairpersons: Frederica Perera, New York, NY;
Paul Kleihues, Lyon, France
Hotel Gellért, Budapest, Hungary

OCTOBER 19-23, 1996

Programmed Cell Death

Chairperson: Stanley J. Korsmeyer, St. Louis, MO
The Sagamore, Bolton Landing (Lake George), NY

JANUARY 10-14, 1997

Basic and Clinical Aspects of Lymphoma

Joint Meeting with the American Society of Clinical
Oncology

Chairpersons: Joseph R. Bertino, New York, NY;
James O. Armitage, Omaha, NE
Stouffer Renaissance Esmeralda Resort, Indian
Wells (Palm Springs), CA

JANUARY 17-21, 1997

Disrupted Transcription Factors in Cancer

Chairpersons: Peter K. Vogt, La Jolla, CA; Frank
J. Rauscher III, Philadelphia, PA
Hotel Del Coronado, San Diego, CA

FEBRUARY 13-16, 1997

Growth Factors, Signaling, and Cancer

Joint Meeting with Lorne Cancer Congress
Chairpersons: Antony Burgess, Parkville, Victoria,
Australia; Robert S. Coffey, Nashville, TN;
Ashley R. Dunn, Parkville, Victoria, Australia;
Webster K. Cavenee, La Jolla, CA
Erskine House, Lorne, Victoria, Australia

AACR members will receive brochures on the
above special conferences as soon as they are
available. Nonmembers should call or write:

American Association for Cancer Research
Public Ledger Building, Suite 816
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 • 215-440-9313 (FAX)
E-Mail: aacr@aol.com

The American Association for Cancer Research Presents

Molecular Biology in Clinical Oncology: A Workshop **Supported by a Generous Grant from the National Cancer Institute**

An intensive, one-week summer workshop on molecular biology designed for clinical oncologists in training or in their early academic careers.

June 28-July 4, 1996
Given Biomedical Institute
Aspen, Colorado

ORGANIZERS

STEPHEN H. FRIEND
Fred Hutchinson Cancer
Research Center
Seattle, WA

L. MICHAEL GLODÉ
University of Colorado
School of Medicine
Denver, CO

JENNIFER A. PIETENPOL
Vanderbilt University
School of Medicine
Nashville, TN

- Lectures by leading experts on molecular biology concepts and the latest developments in molecular oncology. Topics include gene therapy, oncogenes and growth factors, tumor suppressor genes, molecular genetics, metastasis genes, and drug design.
- Small group laboratory sessions to demonstrate the important experimental techniques utilized in molecular biology.
- Category I CME credits through the University of Colorado School of Medicine.
- A workshop syllabus containing relevant published papers, references to key articles in the literature, and details on important laboratory procedures.
- Financial support for participants who are physicians in training or oncology fellows.

Faculty

Lectures

ANDRÉ BERNARDS/ Charlestown, MA
KATHLEEN R. CHO/ Baltimore, MD
CYNTHIA A. EDWARDS/ Redwood City, CA
ROBERT N. EISENMAN/ Seattle, WA
ERIC R. FEARON/ Ann Arbor, MI
STEPHEN H. FRIEND/ Seattle, WA

LELAND H. HARTWELL/ Seattle, WA
TYLER JACKS/ Cambridge, MA
MARY-CLAIRE KING/ Seattle, WA
RICHARD D. KLAUSNER/ Bethesda, MD
MARC E. LIPPMAN/ Washington, DC
A. THOMAS LOOK/ Memphis, TN
HAROLD L. MOSES/ Nashville, TN

GARY J. NABEL/ Ann Arbor, MI
ALLEN I. OLIFF/ West Point, PA
JENNIFER A. PIETENPOL/ Nashville, TN
NADIA ROSENTHAL/ Charlestown, MA
PATRICIA S. STEEG/ Bethesda, MD
MIN WU/ Beijing, P. R. C.

Laboratory Rotations

MARK S. BOGUSKI/ Bethesda, MD. "Computer Searching in Molecular Biology."
JULIE A. CAMPAIN/ Denver, CO. "Polymerase Chain Reaction Technology."
JAMES P. HOEFFLER/ San Diego, CA. "Transfer of Nucleic Acids and Proteins."
MARILEILA V. GARCIA/ Denver, CO. "Practical Cytogenetics."
CORI GORMAN/Burlingame, CA. "Gene Expression Systems."

Application Deadline March 25, 1996

For further information, contact

American Association for Cancer Research
Public Ledger Building, Suite 816
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300 • FAX: (215) 440-9313
Email: aacr@aol.com



THE AMERICAN ASSOCIATION FOR CANCER RESEARCH PRESENTS



*An Important Educational Opportunity Primarily for
Predoctoral and Postdoctoral Fellows
Contemplating Careers in Basic Cancer Research*

HISTOPATHOBIOLOGY OF NEOPLASIA

*The Edward A. Smuckler Memorial Workshop
Supported by a Generous Grant from the National Cancer Institute*

Keystone Conference Center
Keystone, Colorado
July 21 - July 28, 1996

- Intensive training in the histopathology and biology of neoplasia.
- Twenty-eight hours of hands-on laboratory exercises directed by distinguished pathologists.
- An outstanding series of lectures on rapidly developing areas of cancer research by laboratory directors and other prominent investigators.
- Extensive written course materials that will serve as valuable references in the future.
- Waiver of registration fee and partial support for students' and fellows' lodging and subsistence expenses during the workshop.

LABORATORY AND LECTURING FACULTY

Helen D. Feiner*, New York University School of
Medicine, New York, NY **Course Director**
Stephen Baird, Veterans Administration Medical
Center, San Diego, CA
Edward Bresnick, University of Massachusetts
Medical Center, Worcester, MA
Arthur R. Brothman, University of Utah,
Salt Lake City, UT
Betty DeMasters, University of Colorado School of
Medicine, Denver, CO
Isaiah J. Fidler, UT M.D. Anderson Cancer Center,
Houston, TX
Michael B. Kastan, Johns Hopkins University
Hospital, Baltimore, MD
Mary-Claire King, University of Washington,
Seattle, WA
John H. Lehman, Albany College of Medicine,
Albany, NY

Michael W. Lieberman, Baylor College of
Medicine, Houston, TX
Reuben Lotan, UT M.D. Anderson Cancer Center,
Houston, TX
Robert Low*, University of Colorado School of
Medicine, Denver, CO
Gary J. Miller*, University of Colorado School of
Medicine, Denver, CO
Harold L. Moses, Vanderbilt University School of
Medicine, Nashville, TN
Karl Munger, Harvard Medical School, Boston, MA
Stewart Sell, University of Texas Medical School,
Houston, TX
Patricia A. Thomas, University of Iowa Hospital and
Clinics, Iowa City, IA
Ann D. Thor, Northwestern University, Chicago, IL
Frederic M. Waldman*, University of California,
San Francisco, CA

Additional Faculty to be Announced

**Member of the Workshop Executive Committee*

APPLICATION DEADLINE: APRIL 30, 1996

Further Information: American Association for Cancer Research • Public Ledger Building
150 S. Independence Mall West • Suite 816 • Philadelphia, PA 19106-3483
Telephone: (215) 440-9300 • FAX: (215) 440-9313 • E-mail: AACR@aol.com

Guidelines for Submitting Disks to American Association for Cancer Research Publications

The word processing packages that we prefer are as follows:

MacWrite	WordPerfect (DOS, Windows, and Macintosh)
Microsoft Word (DOS, Windows, and Macintosh)	XyWrite (DOS and Windows)

Also acceptable:

Ability	Mass 11	SoloWriter
AmiPro	MS Windows Write	Sprint
A _M S-TeX	MS Works	Stx
Appleworks	MS Works WP Mac	SunWrite
ArborTeX	Multimate	Symphony
ArborText	Multimate Advantage	TEX
ClarisWorks WP	Nibia	TeX78
CPT 8000	Nisus (to ASCII file)	Text EXecutive
CTOS	Notewriter	Textures
Diablo	Obun	Total Word
DisplayWrite	OfficeWriter	Troff
Duet	PC Write	μTeX
Einstein	PFS First Choice	Volkswriter
Enable	Professional Write	VuWriter
EXP	Q&A Write	Wang OIS
Final Word	Quark XPress	Wang WPS
FullWrite	RagTime MS Works	Wang Writer
GemWord Plus	(to ASCII file)	Window Works
IBM Writing Assistant	Rich Text Format	Windows Write
Interleaf	RSG (to ASCII file)	WiziWord
LaTeX	Signature	Wordstar
Latex	SLITeX	Wordstar 2000
Leading Edge	SmartWhere	WriteNow
Lotus Manuscript	SmartWrite II	Xerox
Lotus Write		

Software packages that we are unable to translate:

FrameMaker	Ready, Set, Go
PageMaker	Scientific Writer

Disks produced on IBM or IBM-compatible computers are preferred, but those produced on some Apple or Wang computers can also be converted. Because of the file structures and internal coding, we cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. We also cannot guarantee that all special characters can be translated. Tabular and mathematical material, such as equations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the disk file. The tables and equations will be keyed from this hard copy. We also need to know the name of the file to be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system (e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

<p>PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK. DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.</p>



DISK SUBMISSION FORM

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. When submitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along with the required four hard copy printouts. Disks will ultimately be returned to the authors.

See reverse for the word processing packages that can be accepted.

File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the most recently submitted printed copy. The file should contain all the parts of the manuscript in **one** file. Mathematical and tabular material, however, will be processed in the traditional manner and may be excluded from the disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

Please label the outside of the disk with the journal name, the first author's name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. To process your disk efficiently, we need the following information. Please be sure to provide **ALL** the information.

Name used to access paper on disk: _____

Name of computer used (e.g., IBM/PS2): _____

Operating system and version (e.g., DOS 3.3): _____

Word processing program and version (e.g., WordPerfect 5.0): _____

[See reverse for acceptable programs.]

Manuscript number: _____

First author: _____

Corresponding author (if different from first author): _____

Telephone/FAX numbers: _____

This form (both sides) may be reproduced.